dear
editor
decad
ebola
member
ebov
filovirida
famili
highli
pathogen
filament
singlestrand
rna
virus
respons
sporad
selflimit
cluster
ebola
viru
diseas
evd
central
africa
current
outbreak
evd
west
africa
risen
epidem
statu
consid
world
health
organ
public
health
emerg
intern
concern
level
concern
world
health
organ
healthcar
author
provid
base
high
lethal
ebovzair
human
high
communic
though
bodi
fluid
high
incid
infect
primari
healthcar
worker
total
lack
proven
efficaci
drug
vaccin
although
varieti
potenti
ebov
inhibitor
drug
develop
pipelin
none
suffici
human
safeti
data
complic
estim
efficaci
current
crisi
situat
west
one
experiment
drug
zmapp
monoclon
antibodi
cocktail
shown
highli
effect
revers
advanc
evd
nonhuman
howev
rapid
acquisit
ebov
sequenc
variat
recent
demonstr
genom
surveil
current
evd
epidem
suggest
drug
develop
depend
viral
nonvari
protein
sequenc
may
letter
briefli
address
evidencebas
potenti
sever
tolllik
receptor
agonist
latestag
clinic
develop
reduc
morbid
mortal
evd
death
ebov
infect
associ
markedli
impair
coagul
innat
immun
cascad
increas
product
proinflammatori
cytokin
profound
immun
suppress
result
peripher
lymphocyt
apoptosi
lack
adapt
contrast
survivor
infect
ebov
develop
effect
immun
respons
product
ebov
neutral
antibodi
earli
event
ebov
infect
influenc
patient
abil
develop
effect
immun
respons
success
ebov
replic
depend
viral
inhibit
initi
innat
immun
respons
infect
disarm
innat
immun
respons
common
mechan
employ
highli
pathogen
human
virus
includ
influenza
coronaviru
ebov
one
success
emerg
highli
pathogen
virus
evas
innat
immun
interfer
viral
protein
essenti
compon
ebov
replic
matrix
repres
evidencebas
target
potenti
reduct
morbid
mortal
evd
doublestrand
rna
dsrna
common
compon
viral
replic
initi
system
signal
cascad
normal
activ
interferon
ifn
regulatori
factor
lead
product
type
ifn
ifn
activ
multipl
ifn
respons
pathway
necessari
inhibit
viral
replic
includ
transitori
express
enzym
adenyl
synthetas
protein
kinas
r
requir
dsrna
cofactor
activ
circumv
viral
recognit
human
cell
highli
virul
virus
includ
ebola
evolv
differ
strategi
block
biolog
activ
associ
induct
subsequ
multipl
antivir
respons
initi
adapt
immun
multifunct
major
virul
protein
indispens
ebov
replic
compon
viral
polymeras
factor
also
counteract
host
innat
immun
respons
block
cellular
product
respons
type
ifn
transient
gene
activ
key
compon
innat
immun
respons
viral
infect
includ
activ
tolllik
receptor
helicas
melanoma
differentiationassoci
protein
retino
acidinduc
viral
howev
viral
inhibit
dsrna
respons
element
effect
disarm
essenti
compon
innat
immun
respons
particular
posit
charg
ctermin
amino
acid
motif
figur
bind
sequenceindepend
dsrna
result
suppress
multipl
step
ifn
signal
cascad
otherwis
would
lead
broad
antivir
state
strong
activ
innat
adapt
arm
immun
thu
provid
attract
evidencebas
target
antivir
interrupt
ebov
potenti
amelior
pathogenesi
evd
variou
form
dsrna
studi
induc
type
ifn
although
origin
dsrna
studi
efficaci
human
poli
poli
c
found
induc
seriou
advers
event
human
limit
pharmaceut
develop
sever
deriv
surviv
rigor
anim
clinic
test
poli
iclc
oncovir
inc
washington
dc
usa
consist
poli
poli
c
noncoval
adduct
polymer
chain
polyllysin
carboxymethylcellulos
adduct
increas
drug
halflif
steric
hindranc
phosphodiest
backbon
rnase
hydrolysi
studi
clinic
trial
cancer
therapi
adjuv
cancer
poli
poli
rintatolimod
hemispherx
biopharma
inc
philadelphia
pa
usa
design
ifn
induc
markedli
reduc
incid
advers
advent
compar
parent
compound
poli
poli
devoid
adduct
demonstr
antivir
activ
wide
varieti
dna
rna
virus
preclin
test
anim
studi
rintatolimd
efficaci
epitopeexpand
adjuv
highli
pathogen
avian
influenza
viru
drug
evalu
adjuv
varieti
cancer
vaccin
trial
rintatolimod
demonstr
activ
two
doubleblind
placebocontrol
clinic
trial
chronic
fatigu
current
advanc
clinic
trial
treatment
condit
andor
rintatolimod
experiment
pharmaceut
attract
evidencebas
candid
treatment
evd
expand
basi
recent
approv
world
health
organ
use
experiment
pharmaceut
beyond
phase
food
drug
administrationsanct
clinic
trial
help
ensur
avail
product
establish
safeti
profil
suffici
openlabel
clinic
test
analysi
efficaci
use
potenti
drug
clinic
trial
also
help
ensur
reliabl
suppli
clinicalgrad
drug
remov
ethic
dilemma
patient
select
